Brief: Neurometrix's Quell Wearable Neuromodulator To Be Evaluated In Post-Acute Covid-19 Syndrome
24/02/2022 14:13
Feb 24 (Reuters) - NeuroMetrix Inc NURO.O :
* NEUROMETRIX REPORTS THAT QUELL® WEARABLE NEUROMODULATOR TO
BE
EVALUATED IN POST-ACUTE COVID-19 SYNDROME
Source text for Eikon: ID:nGNX5NMGhD
Further company coverage: NURO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on NeuroMetrix
See all newsBrief: Neurometrix To Be Acquired By Electrocore
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13